Sopharma Trading AD

BUL:SFT Stock Report

Market Cap: лв198.7m

Sopharma Trading AD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sopharma Trading AD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth24.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

We're Not Counting On Sopharma Trading AD (BUL:SO5) To Sustain Its Statutory Profitability

Feb 14
We're Not Counting On Sopharma Trading AD (BUL:SO5) To Sustain Its Statutory Profitability

If You Had Bought Sopharma Trading AD's (BUL:SO5) Shares Three Years Ago You Would Be Down 27%

Dec 18
If You Had Bought Sopharma Trading AD's (BUL:SO5) Shares Three Years Ago You Would Be Down 27%

We Wouldn't Rely On Sopharma Trading AD's (BUL:SO5) Statutory Earnings As A Guide

Aug 10
We Wouldn't Rely On Sopharma Trading AD's (BUL:SO5) Statutory Earnings As A Guide

Sopharma Trading AD's (BUL:SO5) Shareholders Are Down 35% On Their Shares

Jul 20
Sopharma Trading AD's (BUL:SO5) Shareholders Are Down 35% On Their Shares

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sopharma Trading AD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

BUL:SFT - Analysts future estimates and past financials data (BGN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20241,857384260N/A
6/30/20241,770352744N/A
3/31/20241,72832-114N/A
12/31/20231,678303348N/A
9/30/20231,61992538N/A
6/30/20231,588132335N/A
3/31/20231,535103040N/A
12/31/20221,4839919N/A
9/30/20221,43821-60-50N/A
6/30/20221,41418-112-101N/A
3/31/20221,37813-149-136N/A
12/31/20211,3368-186-173N/A
9/30/20211,33315-222-219N/A
6/30/20211,26912-209-199N/A
3/31/20211,19012-212-203N/A
12/31/20201,15611-228-217N/A
9/30/20201,06810-208-181N/A
6/30/20201,01710-204-185N/A
3/31/20201,00211-216-194N/A
12/31/20199469-203-182N/A
9/30/20199298-188-174N/A
6/30/20199169-187-170N/A
3/31/20199019-167-154N/A
12/31/20188889-166-154N/A
9/30/20188668-154-143N/A
6/30/20188258N/A-131N/A
3/31/20187768N/A-120N/A
12/31/20177219N/A-115N/A
9/30/201766910N/A-107N/A
6/30/201764210N/A-112N/A
3/31/201762611N/A-104N/A
12/31/201661311N/A-91N/A
9/30/201660210N/A-62N/A
6/30/201660411N/A-23N/A
3/31/201660311N/A6N/A
12/31/201560311N/A22N/A
9/30/201559812N/A9N/A
6/30/201558711N/A-4N/A
12/31/201457611N/A-5N/A
9/30/201456612N/A8N/A
6/30/201455012N/A-32N/A
3/31/201452911N/A-30N/A
12/31/20135079N/A-30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SFT's forecast earnings growth is above the savings rate (3%).

Earnings vs Market: Insufficient data to determine if SFT's earnings are forecast to grow faster than the BG market

High Growth Earnings: Insufficient data to determine if SFT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SFT's revenue is forecast to grow faster than the BG market.

High Growth Revenue: Insufficient data to determine if SFT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SFT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 07:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sopharma Trading AD is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mihail DimitrovFirst Financial Brokerage House